fda compounding semaglutide enforcement november 2025 news Compounded Semaglutide: Safety & Regulation Guide FDA's GLP-1 decision kicks off

Morton, Robert W., Murphy, K

Time was annualized and included as continuous along with the treatment effect (intercept) and an interaction between time and treatment (slope)

Retatrutide administered once weekly subcutaneously for 12 weeks resulted in a dose-dependent placebo-adjusted weight loss of up to 8.96 kg in the highest dose group and a placebo-adjusted HbA1c reduction of up to 1.6% in a phase II trial in individuals with T2DM [125]

For individuals seeking effective, evidence-based approaches to weight management and metabolic health improvement, several MHRA-licensed options are available within the UK healthcare system with well-characterised safety profiles

Compounded microdose protocols from licensed 503A pharmacies should include detailed patient counseling on injection technique, storage, symptom logging, and provider communication